|
FOR IMMEDIATE RELEASE
July 12, 2006
Eisai and Teva Mutually Agree To End Collaboration Agreement for Rasagiline
Eisai Co., Ltd.
Eisai Inc.
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, U.S.A., Chairman and CEO: Hajime Shimizu) jointly announce today that on July 12th, 2006, the companies and Teva Pharmaceutical Industries Ltd. (Headquarters: Jerusalem, Israel, President: Israel Makov) agree to end a collaboration agreement for rasagiline, which was established in May 2003.
Contacts:
Corporate Communications Department
Eisai Co., Ltd.
TEL: +81-3-3817-5120
|
Cathy Pollini
Corporate Planning and Communications
Eisai Inc.
TEL: +1-201-287-2052 |
|
For Print